文献速递肿瘤 PET/CT放射性药物与辐射防护

用于SPECT/MRI和PET/MRI的多模态纳米药物放射性标记的先进方法

Advanced Methods for Radiolabeling Multimodality Nanomedicines for SPECT/MRI and PET/MRI.
PubMed 文献 · J Nucl Med · 2017-10-12

混合MRI与SPECT或PET相机的出现促进了对多模态成像探针的研发兴趣。纳米颗粒已成为构建SPECT/MRI和PET/MRI多模态放射性示踪剂的有吸引力的平台,但放射性标记仍是关键步骤。本文介绍了9种机制不同的纳米颗粒放射性标记方法,展示了从经典方法到现代无螯合或内在方法的演变。

要点

  • 纳米颗粒是构建SPECT/MRI和PET/MRI多模态放射性示踪剂的有吸引力的平台。
  • 经典放射性标记方法通过表面、核心或涂层功能化实现,可能影响颗粒大小、电荷和溶解度。
  • 无螯合放射性标记方法利用纳米颗粒的固有化学特征,避免对药代动力学和毒理学性质的不利影响。

核心结论

  • 纳米颗粒放射性标记的核心挑战是找到替代化学方法,在引入放射性核素的同时不损害构建体的药代动力学和毒理学性质。
  • 解决这一挑战的努力产生了一系列利用纳米颗粒固有化学特征的无螯合放射性标记方法。

研究设计与样本

  • 本文介绍了9种机制不同的纳米颗粒放射性标记方法,展示了纳米颗粒放射化学从经典方法到现代无螯合或内在方法的演变。

主要发现

  • 经典方法通过功能化纳米颗粒表面、核心或涂层进行放射性标记,通常依赖传统金属离子螯合物或辅基化学。
  • 添加放射性标记手柄可能对颗粒大小、电荷和溶解度等重要性质产生显著影响,进而对纳米颗粒的药理学特征产生负面影响。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The advent of hybrid cameras that combine MRI with either SPECT or PET has stimulated growing interest in developing multimodality imaging probes. Countless options are available for fusing magnetically active species with positron- or γ-ray-emitting radionuclides. The initial problem is one of choice: which chemical systems are a suitable basis for developing hybrid imaging agents? Any attempt to answer this question must also address how the physical, chemical, and biologic properties of a unified imaging agent can be tailored to ensure that optimum specificity and contrast are achieved simultaneously for both imaging modalities. Nanoparticles have emerged as attractive platforms for building multimodality radiotracers for SPECT/MRI and PET/MRI. A wide variety of nanoparticle constructs have been utilized as radiotracers, but irrespective of the particle class, radiolabeling remains a key step. Classic methods for radiolabeling nanoparticles involve functionalization of the particle surface, core, or coating. These modifications typically rely on using traditional metal ion chelate or prosthetic group chemistries. Though seemingly innocuous, appending nanoparticles with these radiolabeling handles can have dramatic effects on important properties such as particle size, charge, and solubility. In turn, alterations in the chemical and physical properties of the nanoparticle often have a negative impact on their pharmacologic profile. A central challenge in radiolabeling nanoparticles is to identify alternative chemical methods that facilitate the introduction of a radioactive nuclide without detrimental effects on the pharmacokinetic and toxicologic properties of the construct. Efforts to solve this challenge have generated a range of innovative chelate-free radiolabeling methods that exploit intrinsic chemical features of nanoparticles. Here, the chemistry of 9 mechanistically distinct methods for radiolabeling nanoparticles is presented. This discourse illustrates the evolution of nanoparticle radiochemistry from classic approaches to modern chelate-free or intrinsic methods.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Lamb J, Holland JP. Advanced Methods for Radiolabeling Multimodality Nanomedicines for SPECT/MRI and PET/MRI. J Nucl Med. 2017. PMID: 29025988. doi:10.2967/jnumed.116.187419

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。